A939572 is a potent, and orally bioavailable SCD1 inhibitor with IC50 values of <4 nM and 37 nM for mSCD1 and hSCD1, respectively.

MK-8245 is an liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy.

T-3764518 (T 3764518, T3764518) is a novel potent, orally active SCD1 inhibitor with binding IC50 of 4.7 nM for hSCD1.

YTX-465 (YTX465) is a specific small molecule that rescues yeast from a-Syn cytotoxicity with EC50 of 15 nM, via inhibiting Ole1, the yeast homolog of human stearoyl-CoA desaturase (SCD).

SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer.

DUN41875, also known as SCD1 inhibitor-4, is a potent, orally active stearoylCoA desaturase-1 (SCD1) inhibitor. SCD1 inhibitor-4 can be used for the research of diabetes. DUN41875 was first reported in Bioorgan.Med. Chem. Lett. (2011), 21(6), 1621-1625. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature 

Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC50 value of 0.9 μM.

YTX-7739 is a potent, selective stearoyl-CoA desaturase (SCD) inhibitor with IC50 of 12 nM.YTX-7739 concentration-dependently reduces the fatty acid desaturation index (FADI), the ratio of monounsaturated to saturated fatty acids, with potential to treat synucleinopathies.